1. Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls.
- Author
-
Karaba AH, Morgenlander WR, Johnston TS, Hage C, Pekosz A, Durand CM, Segev DL, Robien MA, Heeger PS, Larsen CP, Blankson JN, Werbel WA, Larman HB, and Tobian AAR
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Antibodies, Neutralizing immunology, Antibodies, Neutralizing blood, Epitopes immunology, Vaccination, Case-Control Studies, Antibodies, Viral blood, Antibodies, Viral immunology, COVID-19 immunology, COVID-19 prevention & control, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Epitope Mapping, Kidney Transplantation, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, Transplant Recipients
- Abstract
Kidney transplant recipients (KTRs) develop decreased antibody titers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared to healthy controls (HCs), but whether KTRs generate antibodies against key epitopes associated with neutralization is unknown. Plasma from 78 KTRs from a clinical trial of third doses of SARS-CoV-2 vaccines and 12 HCs underwent phage display immunoprecipitation and sequencing (PhIP-Seq) to map antibody responses against SARS-CoV-2. KTRs had lower antibody reactivity to SARS-CoV-2 than HCs, but KTRs and HCs recognized similar epitopes associated with neutralization. Thus, epitope gaps in antibody breadth of KTRs are unlikely responsible for decreased efficacy of SARS-CoV-2 vaccines in this immunosuppressed population. Clinical Trials Registration. NCT04969263., Competing Interests: Potential conflicts of interest. D. L. S. reports receiving consulting and/or speaking honoraria from AstraZeneca, CareDx, Moderna Therapeutics, Novavax, Regeneron, Springer Publishing, Houston Methodist, Northwell Health, Optum Health Education, Sanofi, and WebMd. W. A. W. has received consulting and/or speaking fees from AstraZeneca, GlobalData, China Medical Tribune, Medical Learning Institute (CME), and advisory board fees from Novavax. A. H. K. has received consulting fees from Roche Diagnostics and Hologic, Inc; and speaking fees from PRIME Education (CME). H. B. L. is an inventor on an issued patent (US20160320406A) filed by Brigham and Women's Hospital that covers the use of PhIP-Seq for antiviral antibody detection; and is a founder of ImmuneID, Portal Bioscience, Alchemab, and Infinity Bio. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF